By Deena Beasley Oct 7 (Reuters) – Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
EU ENERGY TASK FORCE TO HOLD CALL AT 16H00 CEST TO DISCUSS OIL, DIESEL STOCK…
VIDEO SHOWS: INTERVIEW WITH GARY LINEKER / B-ROLL OF CRISTIANO RONALDO / B-ROLL OF MAN…
By Mike Dolan Oct 7 (Reuters) - As the US third-quarter earnings season gets set…
* Head says former players unfairly criticise current Australia test team * Hayden says selectors…
By Rollo Ross LOS ANGELES, Oct 7 (Reuters) - Aaron Sorkin, the Oscar-winning screenwriter of…
By Helen Reid PARIS, Oct 7 (Reuters) - Longer, hotter summers are disrupting fashion's seasonal…